Project overview
The OSTEOPRINT project aims to revolutionize osteosarcoma research by developing advanced 3D bioprinted models that better mimic the complex tumor microenvironment of metastatic osteosarcoma in the lung. By integrating cutting-edge bioprinting technologies with a novel bioink formulation—which combines methacrylate-modified gelatin (GelMA), hyaluronic acid (HAMA), and decellularized lung matrix—the project seeks to develop a more accurate and physiologically relevant model to study cancer cell behavior and drug responses.
As a collaboration between the Institute for Bioengineering of Catalonia (IBEC) and the Institute for Research in Biomedicine (IRB Barcelona), OSTEOPRINT brings together expertise in tissue engineering and cancer biology, fostering a multidisciplinary approach to improve the predictive accuracy of preclinical models. The project’s objectives include optimizing the bioink composition, developing high-fidelity bioprinted models, validating these models with metastatic osteosarcoma cells, and conducting advanced drug testing.
By reducing reliance on animal models, accelerating development of personalized therapies, and establishing high-throughput drug-screening platforms, OSTEOPRINT aims to set a new standard in cancer research, advancing the field of oncology with the potential of improving patient outcomes.
Project members
IBEC, Associate Researcher
Project Leader
IRB Barcelona, Group Leader
Project Leader
IBEC, Research Assistant
IBEC, PhD Student
IBEC, Research Associate
IRB Barcelona, PhD Student
IRB Barcelona, Research Associate
Jordi Otero
University of Barcelona, Associate Professor
